Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Denali Therapeutics (DNLI) Long-Term Investments (2017 - 2025)

Denali Therapeutics (DNLI) has disclosed Long-Term Investments for 9 consecutive years, with $98.3 million as the latest value for Q4 2025.

  • Quarterly Long-Term Investments fell 72.64% to $98.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $98.3 million through Dec 2025, down 72.64% year-over-year, with the annual reading at $98.3 million for FY2025, 72.64% down from the prior year.
  • Long-Term Investments for Q4 2025 was $98.3 million at Denali Therapeutics, up from $24.7 million in the prior quarter.
  • The five-year high for Long-Term Investments was $490.7 million in Q1 2024, with the low at $7.9 million in Q3 2023.
  • Average Long-Term Investments over 5 years is $227.5 million, with a median of $235.8 million recorded in 2025.
  • The sharpest move saw Long-Term Investments surged 5535.21% in 2024, then plummeted 94.45% in 2025.
  • Over 5 years, Long-Term Investments stood at $425.4 million in 2021, then plummeted by 77.85% to $94.2 million in 2022, then plummeted by 91.61% to $7.9 million in 2023, then surged by 4446.15% to $359.4 million in 2024, then tumbled by 72.64% to $98.3 million in 2025.
  • According to Business Quant data, Long-Term Investments over the past three periods came in at $98.3 million, $24.7 million, and $78.5 million for Q4 2025, Q3 2025, and Q2 2025 respectively.